It’s a good day for Lipitor. And a good day for Pfizer.
This morning, Pfizer
announced that the U.S. FDA had granted Lipitor (atorvastatin) five new indications, including, “reduce the risk of nonfatal heart attacks, fatal and non-fatal strokes, certain types of heart surgery, hospitalization for heart failure, and chest pain in patients with heart disease.”
This comes on the heels of a
retrospective analysis using a managed care database showing a 14% reduction in the risk of cardiovascular events with Lipitor compared to simvastatin. This is real-world clinical outcomes.
The winds of change might be blowing, but it’s still not smooth sailing on East 42nd Street yet.
This morning, Pfizer announced that the U.S. FDA had granted Lipitor (atorvastatin) five new indications, including, “reduce the risk of nonfatal heart attacks, fatal and non-fatal strokes, certain types of heart surgery, hospitalization for heart failure, and chest pain in patients with heart disease.”
This comes on the heels of a retrospective analysis using a managed care database showing a 14% reduction in the risk of cardiovascular events with Lipitor compared to simvastatin. This is real-world clinical outcomes.
The winds of change might be blowing, but it’s still not smooth sailing on East 42nd Street yet.